4 analysts have expressed a variety of opinions on bluebird bio (NASDAQ:BLUE) over the past quarter, offering a diverse set of opinions from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
---|---|---|---|---|---|
Total Ratings | 1 | 2 | 1 | 0 | 0 |
Last 30D | 1 | 2 | 1 | 0 | 0 |
1M Ago | 0 | 0 | 0 | 0 | 0 |
2M Ago | 0 | 0 | 0 | 0 | 0 |
3M Ago | 0 | 0 | 0 | 0 | 0 |
The 12-month price targets, analyzed by analysts, offer insights with an average target of $4.25, a high estimate of $6.00, and a low estimate of $3.00. A decline of 26.09% from the prior average price target is evident in the current average.
![1723752146_0.png](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240816/42421275-0-68cc2fe148e6dd1e4862bff0b64cdd5a.png/big)
Exploring Analyst Ratings: An In-Depth Overview
In examining recent analyst actions, we gain...
Login or create a forever free account to read this news
Sign up/Log in